export interface ArticleSection {
  heading: string;
  content: string;
  list?: string[];
}

export interface ArticleFAQ {
  question: string;
  answer: string;
}

export interface Article {
  slug: string;
  title: string;
  metaTitle: string;
  metaDescription: string;
  keywords: string[];
  publishedDate: string;
  modifiedDate: string;
  category: string;
  readTime: number; // minutes
  excerpt: string;
  sections: ArticleSection[];
  faqs: ArticleFAQ[];
  relatedProducts: string[];
  relatedSlugs: string[];
}

export const articles: Article[] = [
  {
    slug: "bpc-157-research-overview",
    title: "BPC-157 Research Overview: What Scientists Are Studying",
    metaTitle: "BPC-157 Research Overview: What Scientists Are Studying | Vertex Research Labs",
    metaDescription:
      "A research-focused overview of BPC-157 (Body Protection Compound 157), covering its amino acid structure, mechanism studies, preclinical research history, and published literature. Lab use only.",
    keywords: [
      "BPC-157 research",
      "BPC-157 studies",
      "BPC-157 mechanism",
      "BPC-157 peptide science",
      "body protection compound 157 research",
      "BPC-157 preclinical",
      "BPC-157 published research",
      "BPC-157 amino acid sequence",
    ],
    publishedDate: "2025-01-15",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "BPC-157 is a synthetic pentadecapeptide that has attracted significant attention in preclinical research. This overview summarizes its structural properties, receptor interactions studied in the literature, and the published research record.",
    sections: [
      {
        heading: "What Is BPC-157?",
        content:
          "BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein sequence found in human gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and it has a molecular weight of approximately 1419.5 Da. BPC-157 does not occur naturally in isolation; it is a partial sequence isolated from the parent gastric protein BPC and is available only as a synthetic research reference material.",
      },
      {
        heading: "Structural Properties",
        content:
          "As a pentadecapeptide, BPC-157 contains multiple proline residues which confer conformational rigidity, contributing to its relative stability compared to many other peptide sequences. Its chemical formula is C₆₂H₉₈N₁₆O₂₂. In laboratory settings it is supplied as a lyophilized (freeze-dried) powder and requires reconstitution with an appropriate sterile diluent before use in in vitro or in vivo research protocols.",
        list: [
          "Length: 15 amino acids (pentadecapeptide)",
          "Molecular weight: ~1419.5 Da",
          "Formula: C₆₂H₉₈N₁₆O₂₂",
          "Standard supply form: lyophilized powder",
          "Typical research purity standard: ≥99% by HPLC",
        ],
      },
      {
        heading: "Preclinical Research History",
        content:
          "The majority of published BPC-157 research originates from the laboratory of Professor Predrag Sikiric at the University of Zagreb. Studies appearing in journals including Current Pharmaceutical Design, Journal of Applied Physiology, and Journal of Physiology-Paris have examined BPC-157's interactions with nitric oxide (NO) signaling pathways, growth factor receptor expression, and cytoskeletal dynamics in rodent models. These are preclinical animal studies and do not constitute evidence of safety or efficacy in humans.",
      },
      {
        heading: "Key Research Areas in the Published Literature",
        content:
          "Published preclinical investigations have explored several areas of BPC-157 biology. It is important to note that all cited research represents animal or cell-culture findings only and has not been validated in human clinical trials.",
        list: [
          "Nitric oxide (NO) pathway interactions in rodent models",
          "VEGFR2 and FAK receptor expression in cell culture",
          "Tendon-to-bone junction healing models in rats",
          "Gut motility and gastric mucosal models",
          "Cytoskeletal (actin/tubulin) effects in vitro",
        ],
      },
      {
        heading: "Research Purity Standards",
        content:
          "For reproducible laboratory research, BPC-157 reference material should meet a minimum purity threshold of ≥99% as verified by High-Performance Liquid Chromatography (HPLC), with molecular identity confirmation (typically via mass spectrometry). At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Important Research Disclaimer",
        content:
          "All BPC-157 reference materials supplied by Vertex Research Labs are intended strictly for in vitro laboratory research and analytical applications. This material is not approved by the FDA or any regulatory authority for human or veterinary use. Nothing in this article constitutes medical advice, and BPC-157 should not be used outside of an authorized research setting.",
      },
    ],
    faqs: [
      {
        question: "What does BPC stand for in BPC-157?",
        answer:
          "BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid partial sequence derived from the larger BPC protein found in human gastric juice.",
      },
      {
        question: "Is there published clinical trial data on BPC-157?",
        answer:
          "As of 2025, the vast majority of BPC-157 research is preclinical — conducted in cell culture or rodent models. Limited early-phase human studies have been reported but no large-scale randomized controlled trials have been completed or published.",
      },
      {
        question: "What purity should research-grade BPC-157 be?",
        answer:
          "The standard benchmark for research-grade BPC-157 is ≥99% purity as verified by HPLC, with identity confirmation by mass spectrometry. Certificates of Analysis are available on request where applicable.",
      },
      {
        question: "Where can I find published BPC-157 research?",
        answer:
          "PubMed is the primary database for peer-reviewed BPC-157 publications. Searching 'BPC-157' or 'body protection compound 157' returns the majority of indexed studies, predominantly from the Sikiric research group at the University of Zagreb.",
      },
    ],
    relatedProducts: ["bpc-157", "tb-500", "wolverine-blend"],
    relatedSlugs: [
      "tb-500-thymosin-beta-4-research",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "ghk-cu-copper-peptide-guide",
    title: "GHK-Cu Copper Peptide: Laboratory Reference Guide",
    metaTitle: "GHK-Cu Copper Peptide: Laboratory Reference Guide | Vertex Research Labs",
    metaDescription:
      "Comprehensive laboratory reference guide for GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper). Covers structure, copper-binding chemistry, published research, and purity standards for lab use.",
    keywords: [
      "GHK-Cu research",
      "GHK-Cu copper peptide guide",
      "GHK-Cu mechanism",
      "glycyl histidyl lysine copper",
      "copper peptide research",
      "GHK-Cu gene expression research",
      "GHK-Cu antioxidant research",
      "copper binding tripeptide",
    ],
    publishedDate: "2025-01-22",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 6,
    excerpt:
      "GHK-Cu is a naturally occurring copper-binding tripeptide studied extensively in cell biology research. This guide covers its chemistry, copper coordination, published research landscape, and specifications for laboratory use.",
    sections: [
      {
        heading: "What Is GHK-Cu?",
        content:
          "GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper) is a tripeptide-copper(II) complex that occurs naturally in human plasma, saliva, and urine. It was first isolated by Loren Pickart in 1973 and has since become one of the most studied naturally occurring peptides in biochemistry research. The free tripeptide (GHK) has high affinity for copper(II) ions, and the resulting complex (GHK-Cu) is the primary research form.",
      },
      {
        heading: "Copper Coordination Chemistry",
        content:
          "The copper(II) ion in GHK-Cu is coordinated by three nitrogen atoms from the peptide backbone: the N-terminal amine of glycine, the peptide nitrogen between glycine and histidine, and the imidazole nitrogen of histidine. This square-planar coordination geometry is characteristic of type-II copper complexes and is central to GHK-Cu's documented interactions with biological systems in research settings.",
        list: [
          "Metal: Copper(II) (Cu²⁺)",
          "Coordination: Square-planar, 3N donor atoms",
          "Affinity constant for Cu²⁺: ~10¹⁷ M⁻¹ (extremely high)",
          "Molecular weight (GHK): ~340.4 Da",
          "Molecular weight (GHK-Cu): ~403.9 Da",
        ],
      },
      {
        heading: "Published Research Landscape",
        content:
          "GHK-Cu is among the most published naturally occurring peptides in biochemistry. Research by Pickart and colleagues, appearing in International Journal of Molecular Sciences (2015) and Oxidative Medicine and Cellular Longevity (2018), has examined GHK-Cu's modulation of over 4,000 human genes in cell culture models. Additional published work has investigated its interactions with antioxidant enzymes, collagen synthesis pathways, and the ubiquitin-proteasome system in vitro.",
      },
      {
        heading: "Research Applications",
        content:
          "In laboratory settings, GHK-Cu is used as a reference material across several research disciplines. All applications listed represent in vitro or preclinical contexts only.",
        list: [
          "Gene expression modulation studies (microarray, RNA-seq)",
          "Copper-binding peptide chemistry and coordination studies",
          "Antioxidant pathway research (SOD, catalase interactions)",
          "Extracellular matrix and collagen synthesis models",
          "Wound-healing cell migration assays (in vitro scratch assays)",
        ],
      },
      {
        heading: "Purity and Quality Standards",
        content:
          "Research-grade GHK-Cu should meet ≥99% purity by HPLC analysis. Because it is a metal complex, identity confirmation should include both peptide sequence verification and copper content analysis. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Disclaimer",
        content:
          "GHK-Cu reference materials from Vertex Research Labs are supplied exclusively for laboratory research and analytical purposes. This material is not intended for human or veterinary use. Nothing in this guide constitutes medical advice or a health claim.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between GHK and GHK-Cu?",
        answer:
          "GHK is the free tripeptide (Glycyl-L-Histidyl-L-Lysine). GHK-Cu is the copper(II) complex of GHK. The copper-complexed form is the primary subject of biological research as the copper coordination is central to its documented activities in cell culture studies.",
      },
      {
        question: "How many genes has GHK-Cu been studied in relation to?",
        answer:
          "Microarray and RNA-seq studies in cell culture have examined GHK-Cu's influence on over 4,000 human genes, according to publications by Pickart and colleagues. These are in vitro findings and do not represent clinical outcomes.",
      },
      {
        question: "Is GHK-Cu naturally occurring?",
        answer:
          "Yes. GHK-Cu occurs naturally in human plasma (at approximately 200 ng/mL in young adults, declining with age), as well as in saliva and urine. The synthetic research form is produced to provide consistent, high-purity reference material for laboratory studies.",
      },
      {
        question: "What form does research-grade GHK-Cu ship in?",
        answer:
          "GHK-Cu is supplied as a lyophilized powder in sealed research vials. It is available in 50mg and 100mg formats from Vertex Research Labs.",
      },
    ],
    relatedProducts: ["ghk-cu", "ghk-cu-100", "epithalon", "bpc-157"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "mots-c-mitochondrial-peptide-research",
    title: "MOTS-c: The Mitochondrial-Derived Peptide Redefining Longevity Research",
    metaTitle: "MOTS-c Research Overview: Mitochondrial-Derived Peptide | Vertex Research Labs",
    metaDescription:
      "Research overview of MOTS-c, a mitochondria-encoded peptide identified in Cell Metabolism (2015). Covers its mitochondrial origin, metabolic signaling research, and why it is trending in longevity science.",
    keywords: [
      "MOTS-c research",
      "mitochondrial derived peptide",
      "MOTS-c Cell Metabolism",
      "MOTS-c longevity research",
      "MOTS-c metabolic signaling",
      "mitokine research",
      "MOTS-c 12S rRNA",
      "MOTS-c preclinical",
      "trending longevity peptides 2025",
    ],
    publishedDate: "2025-02-10",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — an entirely new class of signaling molecule. Since its landmark identification in Cell Metabolism (2015), it has become one of the most actively studied peptides in longevity and metabolic research.",
    sections: [
      {
        heading: "What Is MOTS-c?",
        content:
          "MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by a short open reading frame within the 12S ribosomal RNA gene of the human mitochondrial genome. Its discovery, reported by Lee C et al. in Cell Metabolism (2015), established a new category of bioactive molecules: mitochondria-derived peptides (MDPs), also called mitokines. MOTS-c's sequence is MRWQEMGYIFYPRKLR.",
      },
      {
        heading: "A New Category: Mitochondria-Derived Peptides",
        content:
          "For decades, the mitochondrial genome was considered to encode only 13 proteins, 22 tRNAs, and 2 rRNAs — all components of the oxidative phosphorylation machinery. The discovery of MOTS-c and other short open reading frames within mitochondrial non-coding regions expanded this understanding fundamentally. MDPs are now recognized as a distinct class of signaling molecules that can translocate from mitochondria to the cytoplasm and nucleus, acting as retrograde signals between mitochondria and the rest of the cell.",
        list: [
          "Source: Mitochondrial 12S rRNA gene small open reading frame",
          "Length: 16 amino acids",
          "Sequence: MRWQEMGYIFYPRKLR",
          "Molecular weight: ~2174.5 Da",
          "Classification: Mitochondria-Derived Peptide (MDP) / Mitokine",
        ],
      },
      {
        heading: "Published Research: Metabolic Signaling",
        content:
          "The landmark 2015 Cell Metabolism paper (Lee C et al., DOI: 10.1016/j.cmet.2015.01.020) demonstrated that MOTS-c regulates the AMPK pathway and methionine metabolism via the folate cycle in cell and animal models. Subsequent research has examined MOTS-c's translocation to the nucleus under stress conditions and its interactions with ARE (Antioxidant Response Element) pathways. All findings to date are preclinical.",
      },
      {
        heading: "Why MOTS-c Is Trending in Longevity Research",
        content:
          "Several factors have converged to make MOTS-c one of the most-discussed peptides in longevity science circles as of 2024–2025.",
        list: [
          "Published in Cell Metabolism — one of the highest-impact journals in metabolic biology",
          "Novel mechanism: mitochondrial genome origin was unexpected",
          "AMPK pathway relevance connects it to established longevity research (metformin, rapamycin literature)",
          "Age-related decline in circulating MOTS-c levels observed in published studies",
          "Active ongoing research from multiple independent laboratories",
        ],
      },
      {
        heading: "Research Grade MOTS-c Specifications",
        content:
          "MOTS-c is available from Vertex Research Labs in 10mg and 40mg formats, both independently verified at ≥99% purity by HPLC. Given its relatively short sequence and unique amino acid composition, identity confirmation via mass spectrometry is standard in our quality protocol. Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Disclaimer",
        content:
          "MOTS-c reference materials from Vertex Research Labs are supplied exclusively for laboratory research use. No claims are made regarding any therapeutic, health, or clinical application. All research findings cited are preclinical and do not establish safety or efficacy in humans.",
      },
    ],
    faqs: [
      {
        question: "Where is MOTS-c encoded in the human genome?",
        answer:
          "MOTS-c is encoded within a short open reading frame in the 12S ribosomal RNA gene of the mitochondrial genome — not the nuclear genome. This makes it part of a newly discovered class called mitochondria-derived peptides (MDPs).",
      },
      {
        question: "What pathway does MOTS-c research focus on?",
        answer:
          "Published research has primarily focused on MOTS-c's interactions with the AMPK (AMP-activated protein kinase) pathway and methionine metabolism via the folate cycle, as identified in the 2015 Cell Metabolism paper by Lee et al.",
      },
      {
        question: "Is MOTS-c levels known to change with age?",
        answer:
          "Published studies have reported an age-related decline in circulating MOTS-c levels in both mice and humans, which has contributed to significant interest in this peptide within the longevity research community.",
      },
      {
        question: "What sizes is MOTS-c available in for research?",
        answer:
          "Vertex Research Labs offers MOTS-c in 10mg (standard) and 40mg (bulk) formats, both at ≥99% purity. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["mots-c", "mots-c-40", "nad-plus", "epithalon"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "bpc-157-research-overview",
    ],
  },

  {
    slug: "epithalon-research-overview",
    title: "Epithalon (Epitalon) Research: A Tetrapeptide Overview",
    metaTitle: "Epithalon (Epitalon) Research Overview: Telomere & Longevity Science | Vertex Research Labs",
    metaDescription:
      "Research overview of Epithalon (Epitalon), the synthetic tetrapeptide Ala-Glu-Asp-Gly studied for telomerase interactions and pineal biology. Covers structure, published studies, and research specifications.",
    keywords: [
      "Epithalon research",
      "Epitalon research",
      "Epithalon telomere research",
      "Epithalon telomerase",
      "Epitalon peptide studies",
      "Epithalon Khavinson",
      "pineal peptide research",
      "tetrapeptide longevity research",
      "Epithalon preclinical",
      "longevity peptide research",
    ],
    publishedDate: "2025-02-18",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 6,
    excerpt:
      "Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a pineal gland extract. Research by Khavinson and colleagues has examined its interactions with telomerase activity and chromatin structure in cell culture models, making it one of the most discussed peptides in longevity research.",
    sections: [
      {
        heading: "What Is Epithalon?",
        content:
          "Epithalon (also spelled Epitalon; IUPAC: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It was derived from Epithalamin — a complex polypeptide extract of the bovine pineal gland that Khavinson's group studied beginning in the 1980s. Epithalon represents the isolated active tetrapeptide sequence from that larger extract and is the form used in modern research.",
        list: [
          "Sequence: Ala-Glu-Asp-Gly (AEDG)",
          "Molecular weight: ~390.35 Da",
          "Formula: C₁₄H₂₂N₄O₁₀",
          "Classification: Synthetic tetrapeptide / bioregulator",
          "Source of derivation: Epithalamin (bovine pineal extract)",
        ],
      },
      {
        heading: "Pineal Biology and Research Context",
        content:
          "The pineal gland is a small endocrine structure in the brain responsible for melatonin secretion and involved in circadian rhythm regulation. Khavinson's research group pursued the hypothesis that peptide bioregulators derived from various organs carry tissue-specific biological information. Epithalamin (and subsequently Epithalon) was their pineal-derived candidate. The majority of foundational Epithalon research originates from Khavinson's laboratory and affiliated Russian institutes.",
      },
      {
        heading: "Telomerase Research",
        content:
          "The area of Epithalon research attracting the most contemporary attention involves telomerase — the enzyme responsible for maintaining telomere length at chromosome ends. A study published in Bulletin of Experimental Biology and Medicine (Khavinson VK et al., 2003) reported telomerase activation in human somatic cells treated with Epithalon in vitro. This single finding has generated substantial interest, though independent replication in peer-reviewed literature remains limited. Researchers should interpret these findings in that context.",
      },
      {
        heading: "Chromatin and Gene Expression Research",
        content:
          "Beyond telomerase, Khavinson's group has published research examining Epithalon's interactions with chromatin structure and gene promoter regions. The proposed mechanism involves Epithalon binding to histone proteins and influencing chromatin accessibility, which would affect transcription factor binding. These findings are from cell culture and animal models only.",
      },
      {
        heading: "Why Epithalon Is Trending",
        content:
          "Several factors explain Epithalon's growing search volume and community interest in 2024–2025.",
        list: [
          "Telomere biology has become a high-profile research area following Nobel Prize recognition (Blackburn, Greider, Szostak, 2009)",
          "Longevity research is experiencing broader public and scientific interest",
          "Epithalon is one of the few peptides with published (though limited) telomerase interaction data",
          "It is relatively affordable as a research material compared to longer peptides",
          "Active discussion in longevity research communities online has driven search interest",
        ],
      },
      {
        heading: "Research Grade Specifications",
        content:
          "Epithalon is supplied by Vertex Research Labs in 10mg vials at ≥99% purity, independently verified by HPLC. Certificates of Analysis are available on request where applicable. As a tetrapeptide, it is among the smaller peptide reference materials in our catalog, which contributes to its stability and relatively accessible price point.",
      },
      {
        heading: "Disclaimer",
        content:
          "Epithalon reference materials from Vertex Research Labs are supplied for laboratory research use only. Published research on Epithalon is predominantly from a single research group and has not been extensively independently replicated. No therapeutic, anti-aging, or health claims are made. This material is not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between Epithalon and Epithalamin?",
        answer:
          "Epithalamin is a complex polypeptide extract derived from bovine pineal glands. Epithalon (Ala-Glu-Asp-Gly) is the synthetic tetrapeptide identified as the active sequence within Epithalamin and is the standard form used in modern research.",
      },
      {
        question: "What is Epithalon's proposed interaction with telomerase?",
        answer:
          "A 2003 publication in Bulletin of Experimental Biology and Medicine by Khavinson et al. reported telomerase activation in human somatic cells treated with Epithalon in vitro. Independent replication of this finding in peer-reviewed literature remains limited.",
      },
      {
        question: "Is Epithalon the same as Epitalon?",
        answer:
          "Yes. Epithalon and Epitalon are two common spellings of the same tetrapeptide (Ala-Glu-Asp-Gly). The 'Epithalon' spelling is more common in English-language scientific literature.",
      },
      {
        question: "What purity is research-grade Epithalon?",
        answer:
          "Vertex Research Labs supplies Epithalon at ≥99% purity verified by HPLC. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["epithalon", "ghk-cu", "mots-c", "dsip"],
    relatedSlugs: [
      "mots-c-mitochondrial-peptide-research",
      "ghk-cu-copper-peptide-guide",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "how-to-read-peptide-coa",
    title: "How to Read a Peptide Certificate of Analysis (COA)",
    metaTitle: "How to Read a Peptide Certificate of Analysis (COA) | Vertex Research Labs",
    metaDescription:
      "A complete guide to reading and verifying a peptide Certificate of Analysis. Covers HPLC purity data, mass spectrometry identity confirmation, batch numbers, and what to look for when evaluating a supplier.",
    keywords: [
      "how to read peptide COA",
      "peptide certificate of analysis",
      "HPLC peptide purity",
      "peptide COA explained",
      "peptide batch documentation",
      "verify peptide purity",
      "what is peptide COA",
      "research peptide quality verification",
      "mass spectrometry peptide identity",
      "peptide purity standards",
    ],
    publishedDate: "2025-03-01",
    modifiedDate: "2025-04-01",
    category: "Research Guide",
    readTime: 8,
    excerpt:
      "A Certificate of Analysis (COA) is the primary document for verifying peptide quality in research settings. This guide explains every section of a COA — from HPLC chromatograms to mass spec data — and what standards to hold suppliers to.",
    sections: [
      {
        heading: "What Is a Certificate of Analysis?",
        content:
          "A Certificate of Analysis (COA) is a quality assurance document issued for a specific batch of a compound. For research peptides, it provides analytical evidence that the material meets specified purity, identity, and quality standards. A COA is not a guarantee of safety or fitness for any particular use — it is a technical document confirming what the material is and how pure it is. COA practices vary by supplier; request whatever documentation is available and review the purity and identity data it provides.",
      },
      {
        heading: "Key Sections of a Peptide COA",
        content:
          "A complete peptide COA typically contains the following elements.",
        list: [
          "Product name and catalog number",
          "Batch / lot number (where provided)",
          "Date of analysis",
          "Testing laboratory name (third-party independent is the gold standard)",
          "Purity result (% by HPLC, with chromatogram)",
          "Identity confirmation (mass spectrometry or amino acid analysis)",
          "Appearance description (e.g. white lyophilized powder)",
          "Storage conditions",
          "Analyst signature or laboratory stamp",
        ],
      },
      {
        heading: "Understanding HPLC Purity Data",
        content:
          "High-Performance Liquid Chromatography (HPLC) is the standard method for determining peptide purity. In a reverse-phase HPLC run, the peptide is separated from impurities based on hydrophobicity. The result is a chromatogram — a graph of UV absorbance (y-axis) versus time (x-axis). The main peak represents your peptide; smaller peaks represent impurities. Purity is calculated as the area of the main peak divided by the total area of all peaks, expressed as a percentage. Research-grade peptides should show ≥99% purity by this method, meaning the main peak accounts for at least 99% of total peak area.",
      },
      {
        heading: "Understanding Mass Spectrometry Identity Confirmation",
        content:
          "HPLC tells you how pure the material is but not definitively what it is. Mass spectrometry (MS) — typically ESI-MS or MALDI-TOF — provides molecular weight confirmation. The measured molecular ion (M+H)⁺ or (M+2H)²⁺ should match the theoretical molecular weight of the peptide within acceptable mass accuracy (typically ±0.1 Da for ESI-MS). For example, BPC-157 has a theoretical MW of 1419.5 Da; a COA showing [M+H]⁺ = 1420.5 is consistent. A mismatch indicates wrong identity or significant structural modification.",
      },
      {
        heading: "Third-Party vs. In-House Testing",
        content:
          "There is an important distinction between in-house COAs and third-party independent COAs. An in-house COA is generated by the supplier's own laboratory — there is a conflict of interest since the supplier is testing their own product. A third-party independent COA is generated by a laboratory with no commercial relationship to the supplier. Third-party COAs are the gold standard in research peptide quality verification. At Vertex Research Labs, all COAs are produced by independent analytical laboratories.",
      },
      {
        heading: "How COA Documentation Can Vary",
        content:
          "COA documentation varies between suppliers. Some COAs reference a unique lot number tied to a specific production run, while others summarize analytical data for a compound more generally. When a lot number is present, it can be cross-referenced against the documentation provided. COA practices differ across the industry; request whatever documentation is available and review the purity and identity data it contains.",
      },
      {
        heading: "Red Flags to Watch For",
        content:
          "When reviewing a peptide COA, these are common indicators of incomplete documentation.",
        list: [
          "No testing laboratory identified",
          "HPLC purity listed without a chromatogram",
          "No mass spectrometry data",
          "Analysis date that predates the supplier's business existence",
          "Purity stated as 'tested by manufacturer' with no third-party reference",
          "COA with no analyst name or laboratory signature",
        ],
      },
    ],
    faqs: [
      {
        question: "What does ≥99% purity by HPLC mean?",
        answer:
          "It means that in the HPLC chromatogram, the peak corresponding to the target peptide accounts for at least 99% of the total peak area. The remaining ≤1% may include synthesis byproducts, degradation products, or residual reagents.",
      },
      {
        question: "Is HPLC purity the same as mass spectrometry identity?",
        answer:
          "No — they measure different things. HPLC measures purity (how much of the sample is the target compound vs. impurities). Mass spectrometry confirms molecular identity (that the compound has the correct molecular weight). Both should be present on a complete COA.",
      },
      {
        question: "Should a COA come from a third-party lab?",
        answer:
          "Third-party independent COAs are the gold standard because there is no conflict of interest — the testing laboratory has no financial stake in the result. In-house COAs are less reliable for this reason.",
      },
      {
        question: "How is a COA related to a specific lot?",
        answer:
          "When a COA includes a lot or batch number, that identifier can be cross-referenced against the documentation. COA practices vary by supplier, so review whatever documentation is provided alongside the purity and identity data.",
      },
      {
        question: "What purity should I expect for research-grade peptides?",
        answer:
          "The accepted benchmark for research-grade peptides is ≥99% purity by HPLC. Materials below 98% are generally considered below research grade and may introduce confounding variables into experimental results.",
      },
    ],
    relatedProducts: ["bpc-157", "ghk-cu", "tb-500", "rp-300"],
    relatedSlugs: [
      "research-grade-peptide-purity-standards",
      "bpc-157-research-overview",
      "ghk-cu-copper-peptide-guide",
    ],
  },

  {
    slug: "tb-500-thymosin-beta-4-research",
    title: "TB-500 (Thymosin Beta-4): Preclinical Research Overview",
    metaTitle: "TB-500 Thymosin Beta-4 Research Overview | Vertex Research Labs",
    metaDescription:
      "Preclinical research overview of TB-500 (Thymosin Beta-4 Acetate). Covers actin-binding properties, cytoskeletal research, published literature, and why it is one of the most studied peptides in preclinical science.",
    keywords: [
      "TB-500 research",
      "Thymosin Beta-4 research",
      "TB-500 preclinical",
      "Thymosin Beta-4 actin binding",
      "TB-500 cytoskeletal research",
      "Tβ4 published studies",
      "TB-500 mechanism",
      "Thymosin Beta-4 cell migration",
    ],
    publishedDate: "2025-02-25",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "TB-500 is the synthetic analog of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding peptide. It has one of the largest published preclinical research bodies of any peptide reference material, with studies appearing in FASEB Journal, Annals of the New York Academy of Sciences, and numerous other journals.",
    sections: [
      {
        heading: "What Is TB-500?",
        content:
          "TB-500 is the synthetic form of the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. Tβ4 is one of the most abundant intracellular peptides in eukaryotic cells and plays a central role in regulating actin polymerization. TB-500 as a research material is typically the 17-amino-acid fragment representing the actin-binding domain, though formulations may vary. Vertex Research Labs supplies TB-500 / Thymosin Beta-4 Acetate as the full-length synthetic equivalent.",
        list: [
          "Natural source: Encoded by the TMSB4X gene on the X chromosome",
          "Length: 43 amino acids (Tβ4 full length) / 17 aa actin-binding fragment",
          "Molecular weight (Tβ4 acetate): ~4963.5 Da",
          "Primary function: Actin monomer (G-actin) sequestration",
          "Intracellular abundance: One of the highest-concentration peptides in mammalian cells",
        ],
      },
      {
        heading: "Actin Biology and the Role of Thymosin Beta-4",
        content:
          "To understand TB-500 research, understanding actin biology is essential. Actin exists in two forms: monomeric G-actin (globular) and filamentous F-actin. The dynamic balance between G-actin and F-actin — controlled by proteins including Thymosin Beta-4 — regulates cell motility, shape, and cytoskeletal structure. Tβ4 acts as a G-actin sequestering protein, binding free actin monomers and modulating when and where new actin filaments can form. This places it at the center of cytoskeletal biology research.",
      },
      {
        heading: "Published Research Highlights",
        content:
          "The Thymosin Beta-4 / TB-500 research literature is extensive. Key published works include foundational studies by Goldstein AL and colleagues in Annals of the New York Academy of Sciences (1997) characterizing the peptide's biological properties, and work by Philp D et al. in FASEB Journal (2011) examining cell migration models. Research by Huff T et al. and others has characterized the structural basis of actin binding at atomic resolution. All cited research is preclinical.",
      },
      {
        heading: "Research Areas Covered in the Literature",
        content:
          "The published TB-500 / Tβ4 literature spans multiple research disciplines, reflecting the peptide's central role in cytoskeletal biology.",
        list: [
          "Actin polymerization dynamics and G-actin sequestration",
          "Cell migration assays (scratch assays, transwell models)",
          "Cardiac fibroblast and cardiomyocyte models",
          "Corneal epithelial cell research",
          "Tendon cell proliferation and migration in vitro",
          "Angiogenesis models (endothelial cell tube formation)",
        ],
      },
      {
        heading: "TB-500 and BPC-157: Frequently Co-Researched",
        content:
          "TB-500 and BPC-157 are among the most frequently co-studied peptides in the preclinical literature. Researchers investigating cytoskeletal dynamics, tissue remodeling models, or growth factor signaling often use both as reference materials in parallel experimental arms. Vertex Research Labs offers both individually and as the Wolverine Blend (BPC-157 5mg + TB-500 5mg) for researchers who need both in a single verified vial.",
      },
      {
        heading: "Disclaimer",
        content:
          "TB-500 / Thymosin Beta-4 Acetate reference materials from Vertex Research Labs are supplied for laboratory research use only. All research cited is preclinical. No claims regarding human therapeutic use are made. This material is not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "Is TB-500 the same as Thymosin Beta-4?",
        answer:
          "TB-500 is the synthetic form associated with the actin-binding active region of Thymosin Beta-4 (Tβ4). The natural peptide is 43 amino acids; TB-500 may refer to the full synthetic equivalent or the active 17-amino-acid fragment depending on the formulation. Vertex Research Labs supplies TB-500 / Thymosin Beta-4 Acetate.",
      },
      {
        question: "What makes TB-500 important in cytoskeletal research?",
        answer:
          "Thymosin Beta-4 is one of the primary G-actin sequestering proteins in eukaryotic cells, placing it at a central regulatory node in cytoskeletal dynamics. This makes it a highly relevant reference tool for any research involving cell motility, migration, or cytoskeletal remodeling.",
      },
      {
        question: "What purity is research-grade TB-500?",
        answer:
          "Vertex Research Labs supplies TB-500 at ≥99% purity by HPLC. Given its larger molecular weight (~4963 Da), mass spectrometry identity confirmation is standard. Certificates of Analysis are available on request where applicable.",
      },
      {
        question: "Can TB-500 and BPC-157 be ordered together?",
        answer:
          "Yes — they are available individually or as the Wolverine Blend (5mg BPC-157 + 5mg TB-500 in a single co-lyophilized vial) for researchers studying both peptides in the same protocol.",
      },
    ],
    relatedProducts: ["tb-500", "bpc-157", "wolverine-blend"],
    relatedSlugs: [
      "bpc-157-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "research-grade-peptide-purity-standards",
    title: "Research Grade Peptides: What Purity Standards Actually Mean",
    metaTitle: "Research Grade Peptide Purity Standards Explained | Vertex Research Labs",
    metaDescription:
      "What does '≥99% purity' actually mean for research peptides? A clear explanation of HPLC purity grading, why it matters for reproducible research, and how to evaluate supplier quality claims.",
    keywords: [
      "research grade peptide purity",
      "peptide purity standards",
      "99% purity peptide meaning",
      "HPLC peptide grade",
      "research peptide quality",
      "how pure should research peptides be",
      "peptide purity vs research grade",
      "best purity peptides for research",
      "peptide supplier quality",
    ],
    publishedDate: "2025-03-15",
    modifiedDate: "2025-04-01",
    category: "Research Guide",
    readTime: 6,
    excerpt:
      "The phrase 'research grade' is used widely in the peptide industry, but what does it actually mean? This guide demystifies purity grades, explains what HPLC purity numbers represent, and explains why purity matters for experimental reproducibility.",
    sections: [
      {
        heading: "What Does 'Research Grade' Mean?",
        content:
          "Unlike pharmaceutical grade (which is governed by official pharmacopoeias such as USP or BP), 'research grade' is not a formally regulated term. In practice, however, the scientific community has converged on clear standards. Research-grade peptides are expected to meet ≥99% purity by HPLC, with confirmed molecular identity by mass spectrometry and full batch documentation. Materials below this threshold are generally considered substandard for use in peer-reviewed research where data reproducibility is required.",
      },
      {
        heading: "Purity Grades Explained",
        content:
          "Peptide suppliers typically offer materials across several purity tiers. Understanding these helps researchers select the right material for their protocol.",
        list: [
          "≥95% purity: Minimum acceptable for exploratory screening; not suitable for publications",
          "≥98% purity: Acceptable for some research applications; still carries meaningful impurity load",
          "≥99% purity: The accepted research-grade standard; suitable for most published research protocols",
          "≥99.5% purity: High-purity grade; preferred for sensitive assays or reference standard use",
          "Pharmaceutical grade (USP/BP): Governed by official pharmacopoeias; not the same as research grade",
        ],
      },
      {
        heading: "Why Purity Matters for Research Reproducibility",
        content:
          "In a biological assay, a peptide at 95% purity contains 5% unknowns — synthesis byproducts, truncated sequences, oxidized variants, or residual reagents. In a cell culture experiment, these impurities can interact with receptors, enzymes, or signaling pathways, producing results that have nothing to do with the target peptide. This is a significant source of irreproducibility in peptide research. Using ≥99% purity material with confirmed identity eliminates the vast majority of this confounding factor.",
      },
      {
        heading: "Common Impurities in Synthetic Peptides",
        content:
          "Solid-phase peptide synthesis (SPPS), the standard method for producing research peptides, generates characteristic impurity profiles that a high-quality HPLC analysis should resolve.",
        list: [
          "Deletion sequences (peptides missing one or more amino acids from incomplete coupling)",
          "Truncated sequences (incomplete peptide chains from early termination)",
          "Oxidized variants (methionine, cysteine, or tryptophan oxidation)",
          "Racemized residues (D-amino acid incorporation during synthesis)",
          "Residual protecting groups from SPPS chemistry",
          "TFA salt (trifluoroacetate counter-ion from purification; can affect some biological assays)",
        ],
      },
      {
        heading: "How to Verify Purity Claims",
        content:
          "A supplier claiming ≥99% purity should be able to support that claim with documentation. Useful evidence includes an HPLC chromatogram (not just a percentage number) from an independent laboratory, accompanied by mass spectrometry identity confirmation. These pieces of evidence help a purity claim be independently reviewed.",
      },
      {
        heading: "Vertex Research Labs Quality Standard",
        content:
          "Peptides supplied by Vertex Research Labs meet the ≥99% purity standard as verified by independent HPLC analysis, with mass spectrometry identity confirmation. Certificates of Analysis are available on request where applicable.",
      },
    ],
    faqs: [
      {
        question: "Is ≥99% purity enough for published research?",
        answer:
          "Yes — ≥99% purity by HPLC is the accepted standard for most peer-reviewed research protocols. For highly sensitive assays or reference standard applications, ≥99.5% may be preferred.",
      },
      {
        question: "What is TFA salt and does it matter?",
        answer:
          "TFA (trifluoroacetic acid) is used in peptide purification and leaves a trifluoroacetate counter-ion on the final peptide salt. In most biological assays this is inconsequential, but TFA can be cytotoxic at higher concentrations. For sensitive cell culture assays at high peptide concentrations, acetate salt form peptides are preferable.",
      },
      {
        question: "Can I use 95% purity peptides for research?",
        answer:
          "Technically yes, but the 5% impurity load introduces meaningful risk of confounding results, especially in receptor binding assays or cell-based studies. For any research intended for publication, ≥99% purity is the recommended minimum.",
      },
      {
        question: "How do I know if a supplier's purity claim is real?",
        answer:
          "Request whatever COA documentation is available, ideally showing the HPLC chromatogram (not just the percentage number), the testing laboratory's name, and mass spectrometry data. Reviewing this documentation helps a purity claim be independently assessed.",
      },
    ],
    relatedProducts: ["bpc-157", "ghk-cu", "tb-500", "rp-300"],
    relatedSlugs: [
      "how-to-read-peptide-coa",
      "bpc-157-research-overview",
      "ghk-cu-copper-peptide-guide",
    ],
  },

  {
    slug: "cjc-1295-ipamorelin-research",
    title: "CJC-1295 and Ipamorelin: GH-Axis Research Tools Explained",
    metaTitle: "CJC-1295 and Ipamorelin Research Overview: GHRH + GHS | Vertex Research Labs",
    metaDescription:
      "Research overview of CJC-1295 (No DAC) and Ipamorelin as complementary GH-axis research tools. Covers GHRH receptor vs GHS-R1a pharmacology, published studies, and why researchers use them together.",
    keywords: [
      "CJC-1295 research",
      "Ipamorelin research",
      "CJC-1295 Ipamorelin",
      "GHRH analog research",
      "GH secretagogue research",
      "GHS-R1a agonist",
      "CJC-1295 No DAC",
      "growth hormone research peptide",
      "CJC Ipamorelin blend research",
      "GH axis peptide research",
    ],
    publishedDate: "2025-03-20",
    modifiedDate: "2025-04-01",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "CJC-1295 (No DAC) and Ipamorelin represent two complementary entry points into GH-axis research — one targeting GHRH receptors, the other targeting GHS-R1a. Together they allow researchers to study synergistic GH secretagogue pathways using distinct but compatible receptor tools.",
    sections: [
      {
        heading: "The GH Axis: Two Research-Relevant Pathways",
        content:
          "Growth hormone (GH) secretion from the anterior pituitary is regulated by two primary hypothalamic inputs: GHRH (Growth Hormone-Releasing Hormone), which stimulates GH release via GHRHR, and Somatostatin, which inhibits GH release. A third pathway involves Ghrelin, which stimulates GH via the GHS-R1a receptor. CJC-1295 acts on the GHRH receptor pathway; Ipamorelin acts on the GHS-R1a/ghrelin receptor pathway. This complementary receptor biology is the primary reason they are studied together.",
      },
      {
        heading: "CJC-1295 (No DAC): A GHRH Analog",
        content:
          "CJC-1295 is a synthetic analog of GHRH, modified from the native 44-amino-acid sequence. The 'No DAC' designation refers to the absence of the Drug Affinity Complex — a reactive MPA (maleimidoproprionic acid) group that, in the DAC version, covalently binds to albumin for extended half-life. The No DAC variant has a shorter half-life more suitable for pulsatile GH secretion research protocols. Published pharmacokinetic data appeared in Journal of Clinical Endocrinology & Metabolism (Teichman SL et al., 2006).",
        list: [
          "Target receptor: GHRHR (Growth Hormone-Releasing Hormone Receptor)",
          "Mechanism: GHRH receptor agonist",
          "Key distinction: No DAC = shorter half-life, pulse-friendly",
          "Published in: J Clin Endocrinol Metab 2006; 91:799–805",
        ],
      },
      {
        heading: "Ipamorelin: A Selective GH Secretagogue",
        content:
          "Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist at the GHS-R1a receptor — the ghrelin receptor. Research by Raun K et al. published in European Journal of Endocrinology (1998) characterized Ipamorelin as highly selective for GH release, with minimal stimulation of other pituitary hormones (ACTH, cortisol, prolactin) compared to earlier GH secretagogues like GHRP-6. This selectivity makes it a cleaner research tool for GH-axis studies.",
        list: [
          "Target receptor: GHS-R1a (Ghrelin receptor)",
          "Mechanism: Selective GH secretagogue",
          "Key selectivity: Minimal ACTH/cortisol stimulation vs GHRP-6",
          "Published in: Eur J Endocrinol 1998; 139:552–561",
        ],
      },
      {
        heading: "Why Researchers Use CJC-1295 and Ipamorelin Together",
        content:
          "CJC-1295 and Ipamorelin target distinct but synergistic receptor pathways — GHRHR and GHS-R1a respectively. In preclinical models, co-administration of GHRH analogs and GH secretagogues has demonstrated additive GH secretion effects, as the two pathways converge on different intracellular signaling cascades (cAMP for GHRHR; IP3/PKC for GHS-R1a) within the same somatotroph cell. For researchers studying GH secretion dynamics, this makes the combination particularly informative.",
      },
      {
        heading: "The CJC/IPA Blend from Vertex Research Labs",
        content:
          "Vertex Research Labs offers a pre-blended CJC/IPA Blend containing CJC-1295 (No DAC) 5mg and Ipamorelin 5mg in a single 10mg research vial. Both components are independently verified at ≥99% purity. Certificates of Analysis are available on request where applicable. This format is designed for researchers who need both peptides simultaneously without managing two separate procurement and reconstitution workflows.",
      },
      {
        heading: "Disclaimer",
        content:
          "CJC-1295 and Ipamorelin reference materials from Vertex Research Labs are supplied for laboratory research use only. Neither compound is FDA-approved. Published research cited is preclinical or early-phase clinical only. No health or therapeutic claims are made. Not for human or veterinary use.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between CJC-1295 with DAC and without DAC?",
        answer:
          "CJC-1295 with DAC contains a Drug Affinity Complex that covalently binds albumin, extending half-life to approximately 8 days. Without DAC, the half-life is approximately 30 minutes, similar to native GHRH. The No DAC form is preferred for research protocols studying pulsatile GH dynamics.",
      },
      {
        question: "Why is Ipamorelin considered more selective than other GH secretagogues?",
        answer:
          "Ipamorelin was characterized in a 1998 European Journal of Endocrinology study as stimulating GH release with minimal stimulation of ACTH, cortisol, or prolactin — a cleaner profile than earlier secretagogues like GHRP-2 or GHRP-6, which significantly stimulate corticotropin release.",
      },
      {
        question: "Are CJC-1295 and Ipamorelin available separately?",
        answer:
          "Yes — both are available individually. The CJC/IPA Blend (10mg, 1:1 ratio) is offered for researchers who need both in a single verified reference vial.",
      },
      {
        question: "What purity is the CJC/IPA Blend?",
        answer:
          "Both CJC-1295 and Ipamorelin in the blend are independently verified at ≥99% purity. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["cjc-ipa-blend", "tesamorelin", "mots-c"],
    relatedSlugs: [
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "semax-research-overview",
    title: "Semax Research Overview: ACTH Analog Peptide in Neuroscience Studies",
    metaTitle: "Semax Research Overview: ACTH Analog Peptide Studies | Vertex Research Labs",
    metaDescription:
      "A research-focused overview of Semax, the synthetic ACTH(4-10) analog peptide. Covers its amino acid structure, neuropeptide mechanism studies, published preclinical literature, and laboratory specifications.",
    keywords: [
      "Semax research",
      "Semax peptide research",
      "Semax ACTH analog",
      "Semax mechanism",
      "Semax neuropeptide study",
      "Semax preclinical research",
      "ACTH 4-10 analog research",
      "Semax BDNF research",
      "Semax peptide science",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "Semax is a synthetic heptapeptide analog of the ACTH(4-10) sequence that has been studied extensively in Russian neuroscience research. This overview covers its structure, proposed mechanisms involving BDNF and nerve growth factor pathways, and the published preclinical literature.",
    sections: [
      {
        heading: "What Is Semax?",
        content:
          "Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10). The sequence was developed by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and has accumulated a substantial published literature, particularly from Eastern European neuroscience groups. Unlike full-length ACTH, Semax does not stimulate adrenal cortex activity in preclinical models, making it a distinct research tool for studying neuropeptide signaling without corticotropin side effects.",
      },
      {
        heading: "Structural Properties",
        content:
          "Semax has a molecular formula of C₃₇H₅₁N₉O₁₀S and a molecular weight of approximately 813.9 Da. The C-terminal Pro-Gly-Pro extension of the native ACTH(4-10) sequence confers resistance to enzymatic degradation by endoproteases, improving stability in biological matrices. In research settings it is supplied as a lyophilized powder and is soluble in water and dilute aqueous buffers.",
        list: [
          "Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (7 amino acids)",
          "Molecular weight: ~813.9 Da",
          "Formula: C₃₇H₅₁N₉O₁₀S",
          "Origin: ACTH(4-10) synthetic analog",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "Published Research: BDNF and Neuropeptide Pathways",
        content:
          "A significant body of published preclinical research has examined Semax in the context of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) signaling. Studies appearing in journals including Neuropeptides and Bulletin of Experimental Biology and Medicine have reported upregulation of BDNF mRNA in rodent hippocampal tissue following Semax administration in animal models. Additional published work has investigated Semax's interactions with serotonin and dopamine receptor systems, as well as its effects on cerebral blood flow parameters in rat stroke models. All findings cited represent animal or cell-culture research only.",
      },
      {
        heading: "Key Research Areas",
        content:
          "Published preclinical investigations of Semax have explored several neuroscience research contexts. All represent in vitro or animal model findings that have not been validated in large-scale human clinical trials.",
        list: [
          "BDNF and NGF expression in hippocampal tissue (rodent models)",
          "Neuronal survival in ischemia-reperfusion animal models",
          "Monoamine receptor binding studies (serotonin, dopamine)",
          "Cognitive behavior assays in aged rodent models",
          "Cerebral microcirculation parameters in rat models",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade Semax is supplied as a lyophilized powder with ≥99% purity verified by HPLC. Mass spectrometry confirmation of the correct sequence and molecular weight is included in Certificate of Analysis documentation. Vertex Research Labs sources Semax exclusively from verified synthesis partners. Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "Semax reference materials from Vertex Research Labs are supplied strictly for in vitro laboratory research and analytical applications. This compound is not FDA-approved and is not intended for human or veterinary use. Nothing in this article constitutes medical advice or a therapeutic claim. Researchers should consult all applicable institutional and regulatory guidelines before use.",
      },
    ],
    faqs: [
      {
        question: "What does Semax stand for, and where was it developed?",
        answer:
          "Semax is a coined name for the synthetic ACTH(4-10) analog Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s, and has been registered as a pharmaceutical in Russia and Ukraine, though it remains a research compound elsewhere.",
      },
      {
        question: "How does Semax differ from native ACTH in research models?",
        answer:
          "Native ACTH stimulates cortisol production via the adrenal cortex. The ACTH(4-10) fragment and its Semax analog do not produce this adrenal response in preclinical models, which has made Semax a useful tool for studying ACTH-related neuropeptide signaling in isolation.",
      },
      {
        question: "What BDNF findings have been published for Semax in animal models?",
        answer:
          "Animal model studies have reported elevated BDNF mRNA in hippocampal tissue following Semax administration. These are preclinical findings in rodents and do not constitute evidence of comparable effects in humans.",
      },
      {
        question: "What purity standard is required for Semax in laboratory research?",
        answer:
          "A minimum of ≥99% purity by HPLC is the accepted benchmark for research-grade Semax, accompanied by mass spectrometry identity confirmation. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["semax"],
    relatedSlugs: [
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
      "how-to-read-peptide-coa",
    ],
  },

  {
    slug: "selank-peptide-research",
    title: "Selank Peptide Research: Tuftsin Analog and Anxiolytic Studies",
    metaTitle: "Selank Peptide Research: Tuftsin Analog Studies | Vertex Research Labs",
    metaDescription:
      "Research-focused overview of Selank, the synthetic tuftsin analog heptapeptide. Covers structure, GABAergic and serotonin pathway research, published preclinical literature, and lab purity standards.",
    keywords: [
      "Selank research",
      "Selank peptide research",
      "Selank tuftsin analog",
      "Selank mechanism",
      "Selank anxiolytic research",
      "Selank GABA research",
      "Selank serotonin study",
      "Selank preclinical data",
      "synthetic tuftsin peptide research",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin. Preclinical research has examined its interactions with GABAergic, serotonergic, and dopaminergic systems. This overview summarizes its structure, mechanism studies, and the published research record.",
    sections: [
      {
        heading: "What Is Selank?",
        content:
          "Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide fragment of IgG immunoglobulin that binds to specific receptors on phagocytes and has documented immunomodulatory properties. The Pro-Gly-Pro extension added to the tuftsin core in Selank improves metabolic stability in biological matrices. Selank has been registered as a pharmaceutical preparation in Russia and is a recognized research compound in neuroscience and immunology literature.",
      },
      {
        heading: "Structural Properties",
        content:
          "Selank has an amino acid sequence of Thr-Lys-Pro-Arg-Pro-Gly-Pro with a molecular weight of approximately 751.9 Da and molecular formula C₃₃H₅₇N₁₁O₉. The C-terminal Pro-Gly-Pro tripeptide sequence is the same stabilizing extension found in Semax, conferring resistance to dipeptidyl peptidase and prolyl endopeptidase enzymatic cleavage. For laboratory use it is supplied as a lyophilized powder, soluble in water.",
        list: [
          "Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids)",
          "Molecular weight: ~751.9 Da",
          "Formula: C₃₃H₅₇N₁₁O₉",
          "Parent compound: Tuftsin (Thr-Lys-Pro-Arg)",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "GABAergic and Monoamine System Research",
        content:
          "Published preclinical literature has examined Selank's interactions with GABA-A receptor subunit expression and enkephalinase activity in rodent brain tissue. Studies published in Bulletin of Experimental Biology and Medicine and Doklady Biological Sciences have reported changes in expression of genes encoding GABA-A receptor subunits in rodent hippocampus following Selank administration. Additional published work has investigated monoamine metabolism, including serotonin and dopamine turnover, in rodent brain regions. All cited findings represent animal model research only.",
      },
      {
        heading: "Immunomodulatory Research",
        content:
          "As a tuftsin analog, Selank has been studied in the context of innate immune modulation. Published animal model research has examined cytokine expression profiles, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in response to Selank administration. These studies represent preclinical immunology research and do not constitute clinical evidence of immunomodulatory effects in humans.",
        list: [
          "IL-6 and TNF-α expression in rodent models",
          "Macrophage and phagocyte activity assays (in vitro)",
          "Lymphocyte count modulation in rodent infection models",
          "Enkephalinase activity assays in rodent brain tissue",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade Selank is available as a lyophilized powder at ≥99% HPLC purity, with sequence identity confirmed by mass spectrometry. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "Selank reference materials from Vertex Research Labs are supplied strictly for in vitro laboratory research and analytical applications. This compound is not FDA-approved. Nothing in this article constitutes medical advice. Selank should not be used outside an authorized research setting, and researchers should consult applicable institutional review and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "What is the relationship between Selank and tuftsin?",
        answer:
          "Selank is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide derived from the Fc region of IgG. Selank incorporates the tuftsin core sequence and adds a C-terminal Pro-Gly-Pro extension to improve metabolic stability.",
      },
      {
        question: "What GABAergic findings have been reported for Selank in preclinical research?",
        answer:
          "Rodent studies have reported changes in GABA-A receptor subunit gene expression in hippocampal tissue following Selank administration, as well as alterations in enkephalinase activity. These are preclinical animal model findings only.",
      },
      {
        question: "Is Selank the same compound as Semax?",
        answer:
          "No. Both were developed at the same Russian institution and share a C-terminal Pro-Gly-Pro stabilizing sequence, but their core sequences and primary research profiles differ. Semax is an ACTH(4-10) analog studied primarily in neuropeptide and BDNF signaling research, while Selank is a tuftsin analog studied for GABAergic and immunomodulatory interactions.",
      },
      {
        question: "What purity is required for research-grade Selank?",
        answer:
          "The standard is ≥99% purity by HPLC, confirmed alongside mass spectrometry identity verification. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["selank"],
    relatedSlugs: [
      "semax-research-overview",
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "nad-plus-research-overview",
    title: "NAD+ Research Overview: Nicotinamide Adenine Dinucleotide in Cellular Biology Studies",
    metaTitle: "NAD+ Research Overview: Cellular Biology and Sirtuins | Vertex Research Labs",
    metaDescription:
      "Research overview of NAD+ (nicotinamide adenine dinucleotide), covering its role in redox metabolism, sirtuin activation research, DNA repair studies, and published preclinical literature. For lab research use only.",
    keywords: [
      "NAD+ research",
      "NAD plus research",
      "nicotinamide adenine dinucleotide research",
      "NAD+ sirtuin research",
      "NAD+ aging research",
      "NAD+ PARP research",
      "NAD+ metabolism study",
      "NAD+ mitochondrial research",
      "NMN NAD precursor research",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 8,
    excerpt:
      "NAD+ (nicotinamide adenine dinucleotide) is a fundamental coenzyme in cellular metabolism that has generated substantial research interest as a potential mediator of aging biology, sirtuin activation, and DNA repair. This overview covers its biochemistry, preclinical research landscape, and laboratory specifications.",
    sections: [
      {
        heading: "What Is NAD+?",
        content:
          "Nicotinamide adenine dinucleotide (NAD+) is a dinucleotide coenzyme present in all living cells, consisting of two nucleotides joined by phosphate groups — one containing adenine, and one containing nicotinamide. It exists in two interconvertible forms: the oxidized form (NAD+) and the reduced form (NADH). NAD+ functions as an essential electron carrier in mitochondrial oxidative phosphorylation, where the NAD+/NADH ratio is central to cellular energy metabolism. Beyond its classical role in glycolysis and the citric acid cycle, NAD+ serves as a substrate for a family of enzymes — including sirtuins (SIRTs), poly-ADP-ribose polymerases (PARPs), and cADPR synthases — that have become the focus of extensive aging and metabolic research.",
      },
      {
        heading: "Biochemical Roles in Energy Metabolism",
        content:
          "In mitochondrial respiration, NAD+ accepts hydride equivalents to form NADH, which then donates electrons to Complex I of the electron transport chain. This cycling of NAD+/NADH underpins ATP synthesis in aerobic metabolism. Published cell biology research has shown that NAD+ depletion disrupts mitochondrial membrane potential and reduces ATP output in cell culture models. The published literature from researchers including David Sinclair's group at Harvard Medical School and Johan Auwerx's group at EPFL has described declining NAD+ levels as a characteristic of aging tissue in rodent models.",
        list: [
          "Electron carrier in glycolysis and citric acid cycle",
          "Substrate for Complex I of the mitochondrial electron transport chain",
          "NAD+/NADH ratio: key determinant of mitochondrial redox state",
          "Precursor molecule in cADPR and NAADP calcium signaling research",
        ],
      },
      {
        heading: "Sirtuin Activation Research",
        content:
          "Sirtuins (SIRT1–SIRT7) are a family of NAD+-dependent deacylase enzymes that consume one molecule of NAD+ per deacylation reaction, producing nicotinamide as a byproduct. Published research — including studies in Cell Metabolism and Nature — has linked SIRT1 and SIRT3 activity to mitochondrial biogenesis, fatty acid oxidation regulation, and stress response pathways in rodent models. SIRT1 deacetylates PGC-1α, a master regulator of mitochondrial biogenesis, making NAD+ availability a reported upstream variable in mitochondrial number and function studies in animal models. These findings are preclinical and have not been replicated in large-scale human trials.",
      },
      {
        heading: "DNA Repair and PARP Research",
        content:
          "PARPs (poly-ADP-ribose polymerases), particularly PARP1 and PARP2, are major consumers of NAD+ during DNA strand break repair. Published research has shown that excessive PARP activation — as occurs under conditions of DNA damage — can deplete cellular NAD+ pools in cell culture models. Studies examining the interplay between PARP activity and NAD+ availability have been published in Nature Reviews Molecular Cell Biology and Genes & Development. Research teams have explored PARP inhibition as a strategy to preserve NAD+ levels in aged rodent tissue, with reported improvements in sirtuin activity and mitochondrial function in animal models.",
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade NAD+ is supplied as a lyophilized powder at ≥99% purity by HPLC. Identity is confirmed by mass spectrometry verifying the correct molecular weight of 663.4 Da (free acid form). NAD+ is hygroscopic and should be stored in sealed, desiccated conditions. Vertex Research Labs provides NAD+ in 500mg and 1000mg research formats. Certificates of Analysis are available on request where applicable.",
        list: [
          "Molecular weight: 663.4 Da (free acid)",
          "Formula: C₂₁H₂₇N₇O₁₄P₂",
          "Standard research purity: ≥99% by HPLC",
          "Storage: Desiccated, -20°C recommended for long-term storage",
          "Available formats: 500mg, 1000mg lyophilized powder",
        ],
      },
      {
        heading: "Research Disclaimer",
        content:
          "NAD+ reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical applications only. This material is not intended for human or veterinary use. Nothing in this article constitutes medical advice or a therapeutic claim. Researchers should follow all applicable institutional biosafety and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between NAD+ and NADH in research contexts?",
        answer:
          "NAD+ is the oxidized form that accepts hydride electrons to become NADH. NADH then donates electrons to the mitochondrial electron transport chain. In research contexts, the NAD+/NADH ratio is used as an indicator of cellular redox state and metabolic activity.",
      },
      {
        question: "Why has NAD+ attracted interest in aging biology research?",
        answer:
          "Published preclinical research from multiple groups has described declining NAD+ levels in aging rodent tissue, coinciding with reduced sirtuin activity and mitochondrial function. These associations have made NAD+ a focus of longevity research, though findings are preclinical and have not been validated in large human trials.",
      },
      {
        question: "How do NMN and NR relate to NAD+ in published research?",
        answer:
          "NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that are converted to NAD+ intracellularly via salvage biosynthesis pathways. Published research has compared the efficiency of these precursors versus direct NAD+ supplementation in cell culture and rodent models.",
      },
      {
        question: "What storage conditions are required for research-grade NAD+?",
        answer:
          "NAD+ is hygroscopic and sensitive to moisture. For research applications, storage in sealed, desiccated conditions at -20°C is recommended for long-term stability. Working aliquots can be held at 4°C for short periods.",
      },
      {
        question: "What purity standard should research-grade NAD+ meet?",
        answer:
          "≥99% purity by HPLC is the accepted standard for research-grade NAD+, with identity confirmation by mass spectrometry. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["nad-plus", "nad-plus-1000"],
    relatedSlugs: [
      "mots-c-mitochondrial-peptide-research",
      "epithalon-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "glutathione-tripeptide-research",
    title: "Glutathione Tripeptide Research: Antioxidant Biology and Redox Studies",
    metaTitle: "Glutathione Tripeptide Research: Antioxidant Redox Biology | Vertex Research Labs",
    metaDescription:
      "Research overview of glutathione (GSH), the primary intracellular antioxidant tripeptide. Covers structure, redox cycle chemistry, GSH/GSSG ratio research, published cell biology literature, and lab specifications.",
    keywords: [
      "glutathione research",
      "GSH research",
      "glutathione tripeptide research",
      "glutathione antioxidant study",
      "glutathione redox research",
      "GSH GSSG ratio research",
      "glutathione peroxidase research",
      "intracellular antioxidant research",
      "glutathione cell biology",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "Glutathione (GSH) is the most abundant intracellular antioxidant in mammalian cells, a tripeptide composed of glutamate, cysteine, and glycine. This research overview covers its redox chemistry, the GSH/GSSG cycle, published cell biology findings, and laboratory reference specifications.",
    sections: [
      {
        heading: "What Is Glutathione?",
        content:
          "Glutathione (L-gamma-glutamyl-L-cysteinylglycine, GSH) is a tripeptide synthesized endogenously from L-glutamate, L-cysteine, and glycine by the enzymes glutamate-cysteine ligase (GCL) and glutathione synthetase. It is present in virtually all mammalian cells at intracellular concentrations of 1–10 mM, making it the most abundant intracellular non-protein thiol. The cysteine thiol group (–SH) is the chemically active site responsible for GSH's antioxidant and nucleophilic properties. For research purposes, glutathione is synthesized as a high-purity lyophilized powder rather than isolated from biological sources.",
      },
      {
        heading: "Redox Cycle Chemistry",
        content:
          "The glutathione redox cycle converts GSH to its oxidized disulfide form GSSG in the process of neutralizing reactive oxygen species (ROS). Glutathione peroxidase (GPx) catalyzes the reduction of hydrogen peroxide and lipid hydroperoxides using two GSH molecules, producing GSSG and water. GSSG is recycled back to GSH by glutathione reductase (GR) using NADPH as the electron donor. The GSH/GSSG ratio is widely used in cell biology research as an index of intracellular oxidative stress, with lower ratios indicating greater oxidative burden.",
        list: [
          "GSH + ROS → GSSG (catalyzed by glutathione peroxidase, GPx)",
          "GSSG + NADPH → 2 GSH (catalyzed by glutathione reductase, GR)",
          "Normal intracellular GSH/GSSG ratio: ~100:1 to 50:1",
          "Reduced ratio indicates oxidative stress in cell culture models",
        ],
      },
      {
        heading: "Published Cell Biology Research",
        content:
          "Glutathione has one of the largest published research footprints of any biomolecule. Studies appearing in Free Radical Biology and Medicine, Antioxidants & Redox Signaling, and Journal of Biological Chemistry have examined GSH depletion as a model of oxidative stress in cell culture, the role of glutathione S-transferases (GSTs) in xenobiotic detoxification, and GSH's role in regulating apoptosis pathways through protein S-glutathionylation. Additional published literature has investigated mitochondrial glutathione (mGSH) as a distinct pool that protects against mitochondria-specific oxidative damage.",
      },
      {
        heading: "Research Applications",
        content:
          "In laboratory settings, glutathione reference material is used across multiple research disciplines. All listed applications represent in vitro or preclinical research contexts.",
        list: [
          "Oxidative stress cell culture models (GSH depletion assays)",
          "GSH/GSSG ratio quantification as a redox state biomarker",
          "Glutathione S-transferase (GST) activity assays",
          "Protein S-glutathionylation and thiol redox proteomics",
          "Mitochondrial membrane protection studies in cell culture",
          "Drug detoxification pathway research",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade glutathione (reduced form, GSH) is supplied as a lyophilized powder with ≥99% purity verified by HPLC. The molecular weight of the reduced form is 307.3 Da (C₁₀H₁₇N₃O₆S). GSH is sensitive to oxidation and should be stored under inert gas or in desiccated, low-oxygen conditions. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "Glutathione reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical applications only. This compound is not intended for human or veterinary use. Nothing in this article constitutes a medical claim or health advice.",
      },
    ],
    faqs: [
      {
        question: "What is the difference between reduced glutathione (GSH) and oxidized glutathione (GSSG)?",
        answer:
          "GSH is the active, reduced form with a free thiol group that reacts with ROS. GSSG is the oxidized disulfide form produced after GSH neutralizes a reactive oxygen species. Glutathione reductase regenerates GSH from GSSG using NADPH. The GSH/GSSG ratio is a standard research measure of oxidative stress.",
      },
      {
        question: "Why is cysteine important to glutathione's function in research models?",
        answer:
          "The cysteine residue contains the reactive thiol (–SH) group that acts as the electron donor in ROS neutralization reactions. Without cysteine, glutathione lacks antioxidant activity. Cysteine availability is also the rate-limiting step in GSH biosynthesis, making it a key variable in published oxidative stress research.",
      },
      {
        question: "What is the GSH/GSSG ratio and how is it used in research?",
        answer:
          "The GSH/GSSG ratio represents the proportion of reduced versus oxidized glutathione in a cell or tissue sample. In healthy cell culture models it typically exceeds 50:1. Researchers use this ratio as a quantitative index of oxidative stress; lower ratios indicate greater cellular redox imbalance.",
      },
      {
        question: "How should research-grade glutathione be stored?",
        answer:
          "Reduced glutathione (GSH) is sensitive to oxidation by atmospheric oxygen. Research-grade GSH should be stored in desiccated, low-oxygen conditions, ideally at -20°C. Working solutions should be prepared fresh or stored under nitrogen to minimize oxidation.",
      },
    ],
    relatedProducts: ["glutathione"],
    relatedSlugs: [
      "ghk-cu-copper-peptide-guide",
      "nad-plus-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "kisspeptin-research-overview",
    title: "Kisspeptin Research Overview: Hypothalamic Neuropeptide and HPG Axis Studies",
    metaTitle: "Kisspeptin Research Overview: HPG Axis Neuropeptide Studies | Vertex Research Labs",
    metaDescription:
      "Research overview of Kisspeptin (KP-10/KP-54), the hypothalamic neuropeptide encoded by the KISS1 gene. Covers structure, GPR54/KISS1R mechanism studies, HPG axis research, and published preclinical literature.",
    keywords: [
      "Kisspeptin research",
      "Kisspeptin peptide research",
      "KP-10 research",
      "KISS1 neuropeptide research",
      "GPR54 KISS1R research",
      "kisspeptin HPG axis",
      "kisspeptin GnRH research",
      "kisspeptin hypothalamic peptide",
      "kisspeptin mechanism study",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "Kisspeptin is a family of hypothalamic neuropeptides encoded by the KISS1 gene that function as critical upstream regulators of the hypothalamic-pituitary-gonadal (HPG) axis via activation of the GPR54/KISS1R receptor. This overview covers their structure, receptor pharmacology, published HPG axis research, and laboratory specifications.",
    sections: [
      {
        heading: "What Is Kisspeptin?",
        content:
          "Kisspeptin refers to a family of neuropeptides derived from the product of the KISS1 gene (also known as metastin), originally identified as a tumor metastasis suppressor. The primary forms studied in neuroendocrinology research are Kisspeptin-54 (KP-54, the full 54-amino-acid precursor), Kisspeptin-14 (KP-14), Kisspeptin-13 (KP-13), and Kisspeptin-10 (KP-10), all of which share a conserved C-terminal RF-amide sequence that is essential for receptor binding. KP-10 is the shortest fully active fragment and the most commonly used form in laboratory research due to its compact size and binding efficiency at GPR54/KISS1R.",
      },
      {
        heading: "Structural Properties of KP-10",
        content:
          "KP-10 (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂) is a decapeptide with a C-terminal amide and molecular weight of approximately 1302.5 Da. The C-terminal arginine-phenylalanine (RF-amide) motif is essential for GPR54 receptor binding. KP-10 is supplied as a lyophilized powder and requires reconstitution with water or dilute buffer for laboratory use.",
        list: [
          "KP-10 sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂",
          "Molecular weight (KP-10): ~1302.5 Da",
          "C-terminal amide modification essential for receptor binding",
          "RF-amide motif: conserved across all active kisspeptin fragments",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "GPR54/KISS1R Receptor and HPG Axis Research",
        content:
          "Kisspeptin signals through the GPR54 receptor (also designated KISS1R), a G protein-coupled receptor coupled to Gq. In published neuroendocrinology research, activation of GPR54 by kisspeptin in hypothalamic GnRH neurons triggers GnRH (gonadotropin-releasing hormone) secretion, which cascades to pituitary LH and FSH release — the central mechanism controlling reproductive hormone dynamics in the HPG axis. Landmark studies published in Nature (2003) simultaneously identified kisspeptin-GPR54 signaling as essential for pubertal onset in both mouse models and humans with GPR54 loss-of-function mutations.",
      },
      {
        heading: "Key Preclinical Research Areas",
        content:
          "The published kisspeptin literature spans multiple research domains. All findings cited represent preclinical animal model or in vitro research unless specifically noted.",
        list: [
          "GnRH pulsatility and LH surge regulation in rodent and primate models",
          "GPR54 receptor binding kinetics and downstream Gq signaling (in vitro)",
          "Hypothalamic kisspeptin neuron mapping in rodent arcuate and AVPV nuclei",
          "Puberty onset models in GPR54 knockout mice",
          "Kisspeptin interactions with the negative feedback of gonadal sex steroids",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade Kisspeptin-10 is supplied as a C-terminal amide lyophilized powder at ≥99% HPLC purity. Mass spectrometry confirms correct molecular identity including the amide modification. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "Kisspeptin reference materials from Vertex Research Labs are supplied strictly for in vitro laboratory research and analytical applications. This compound is not FDA-approved and is not intended for human or veterinary use. Nothing in this article constitutes medical advice. Researchers should comply with all applicable institutional and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "What is the relationship between kisspeptin and GnRH in published research?",
        answer:
          "Published neuroendocrinology research has established that kisspeptin neurons in the hypothalamus project to and activate GnRH-releasing neurons via GPR54 receptor binding. This kisspeptin-GnRH signaling axis is considered a primary upstream regulator of reproductive hormone dynamics in animal models.",
      },
      {
        question: "Why is KP-10 preferred over longer kisspeptin forms in laboratory research?",
        answer:
          "KP-10 is the shortest fully active kisspeptin fragment containing the conserved RF-amide receptor-binding motif. Its smaller size (10 amino acids, ~1302.5 Da) simplifies synthesis, purification, and reconstitution while retaining full GPR54 binding activity in in vitro assays.",
      },
      {
        question: "What was the significance of the 2003 Nature kisspeptin papers?",
        answer:
          "Two concurrent 2003 Nature papers independently reported that loss-of-function mutations in GPR54 caused hypogonadotropic hypogonadism in both mice and humans, establishing kisspeptin-GPR54 signaling as essential for normal pubertal development and reproductive axis function. These studies defined kisspeptin as a central neuroendocrine regulator.",
      },
      {
        question: "What purity is required for research-grade Kisspeptin-10?",
        answer:
          "≥99% purity by HPLC is the accepted standard, accompanied by mass spectrometry identity confirmation (including verification of the C-terminal amide modification). Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["kisspeptin"],
    relatedSlugs: [
      "cjc-1295-ipamorelin-research",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "tesamorelin-research-overview",
    title: "Tesamorelin Research Overview: GHRH Analog and Growth Hormone Axis Studies",
    metaTitle: "Tesamorelin Research Overview: GHRH Analog Studies | Vertex Research Labs",
    metaDescription:
      "Research overview of Tesamorelin, the synthetic trans-3-hexenoic acid GHRH(1-44) analog. Covers structure, GHRH receptor pharmacology, published GH/IGF-1 axis research, and lab purity standards.",
    keywords: [
      "Tesamorelin research",
      "Tesamorelin peptide research",
      "Tesamorelin GHRH analog",
      "GHRH receptor research",
      "Tesamorelin mechanism",
      "Tesamorelin GH IGF-1 research",
      "Tesamorelin preclinical study",
      "Tesamorelin Egrifta research",
      "growth hormone releasing hormone analog",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 8,
    excerpt:
      "Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) in which the native GHRH(1-44) sequence is N-terminally modified with a trans-3-hexenoic acid group to extend metabolic stability. This overview covers its structure, GHRH receptor pharmacology, published GH/IGF-1 axis research, and laboratory specifications.",
    sections: [
      {
        heading: "What Is Tesamorelin?",
        content:
          "Tesamorelin is a 44-amino-acid synthetic analog of endogenous human growth hormone-releasing hormone (hGHRH) in which the N-terminus of the native GHRH(1-44) sequence is conjugated to a trans-3-hexenoic acid moiety. This modification prevents dipeptidyl peptidase IV (DPP-IV) cleavage at the Ala²-Asp³ bond, extending the half-life of the molecule compared to native GHRH. Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta for a specific HIV-associated lipodystrophy indication in adults, making it one of the few GHRH analogs with published Phase 3 clinical data, though it remains a research compound in all other contexts.",
      },
      {
        heading: "Structural Properties",
        content:
          "Tesamorelin retains the full GHRH(1-44) amino acid sequence and adds a trans-3-hexenoic acid group at the N-terminal Tyr¹ residue via an amide bond. This modification preserves receptor binding while adding DPP-IV resistance. The molecular weight of Tesamorelin is approximately 5135.8 Da, and it is supplied as a lyophilized powder for laboratory use.",
        list: [
          "Core sequence: GHRH(1-44) — 44 amino acids",
          "N-terminal modification: trans-3-hexenoic acid conjugation",
          "Molecular weight: ~5135.8 Da",
          "DPP-IV resistance: extended vs. native GHRH",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "GHRH Receptor Pharmacology",
        content:
          "Tesamorelin binds to the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on pituitary somatotroph cells. Binding activates adenylyl cyclase via Gαs, increasing intracellular cAMP and triggering GH secretion from pituitary cells. Published in vitro receptor binding studies have demonstrated that the trans-3-hexenoic acid modification does not significantly alter GHRHR affinity relative to native GHRH, while substantially improving plasma half-life in rodent pharmacokinetic experiments.",
      },
      {
        heading: "Published GH/IGF-1 Axis Research",
        content:
          "Phase 3 clinical research on Tesamorelin was conducted in HIV-positive adults with lipodystrophy and published in journals including the New England Journal of Medicine and AIDS. These studies documented effects on GH pulse amplitude and IGF-1 levels in this specific patient population. Beyond the FDA-approved indication, published preclinical research has examined Tesamorelin's effects on somatotroph cell signaling, GH pulse dynamics, and downstream IGF-1 secretion in rodent models. Researchers studying GHRH receptor pharmacology use Tesamorelin as a reference agonist due to its documented receptor selectivity and well-characterized pharmacokinetics.",
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade Tesamorelin is supplied as a lyophilized powder at ≥99% purity by HPLC. Given its size (44 amino acids), identity confirmation by LC-MS/MS is included in Certificate of Analysis documentation. Vertex Research Labs provides Tesamorelin in 2mg and 5mg research formats. Certificates of Analysis are available on request where applicable.",
        list: [
          "Available formats: 2mg, 5mg lyophilized powder",
          "Purity: ≥99% by HPLC",
          "Identity: LC-MS/MS sequence confirmation",
          "Storage: Lyophilized at -20°C; reconstituted solutions at 4°C, short term",
        ],
      },
      {
        heading: "Research Disclaimer",
        content:
          "Tesamorelin reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical purposes only. While Tesamorelin (Egrifta) has FDA approval for a specific clinical indication, the research reference material supplied here is not intended for therapeutic use. Nothing in this article constitutes medical advice. Researchers should consult applicable institutional and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "How does Tesamorelin differ from CJC-1295 as a GHRH analog?",
        answer:
          "Both are GHRH analogs, but they differ structurally and pharmacokinetically. Tesamorelin is a 44-amino-acid GHRH(1-44) analog with a trans-3-hexenoic acid N-terminal modification. CJC-1295 is a truncated GHRH analog optionally conjugated to a Drug Affinity Complex (DAC) that binds albumin. Tesamorelin has been studied in Phase 3 human trials, while CJC-1295 research is primarily preclinical.",
      },
      {
        question: "What is the DPP-IV resistance mechanism in Tesamorelin?",
        answer:
          "DPP-IV cleaves peptides at the Ala-X bond near the N-terminus. The trans-3-hexenoic acid modification at the N-terminal Tyr¹ of GHRH(1-44) sterically blocks DPP-IV access, extending the plasma half-life of Tesamorelin relative to the unmodified GHRH sequence.",
      },
      {
        question: "For what indication was Tesamorelin FDA-approved?",
        answer:
          "Tesamorelin (Egrifta) was approved by the FDA in 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. This approved indication does not extend to other uses, and the research reference material from Vertex Research Labs is not intended for therapeutic application.",
      },
      {
        question: "What purity standard is used for research-grade Tesamorelin?",
        answer:
          "≥99% purity by HPLC, confirmed by LC-MS/MS identity verification, is the standard for research-grade Tesamorelin. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["tesamorelin", "tesamorelin-2mg"],
    relatedSlugs: [
      "cjc-1295-ipamorelin-research",
      "glp1-peptides-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "pt-141-bremelanotide-research",
    title: "PT-141 (Bremelanotide) Research Overview: Melanocortin Receptor Studies",
    metaTitle: "PT-141 Bremelanotide Research Overview: Melanocortin Peptide Studies | Vertex Research Labs",
    metaDescription:
      "Research overview of PT-141 (Bremelanotide), the cyclic peptide melanocortin receptor agonist. Covers structure, MC3R/MC4R pharmacology, published preclinical and clinical research, and lab purity standards.",
    keywords: [
      "PT-141 research",
      "Bremelanotide research",
      "PT-141 melanocortin research",
      "MC4R agonist research",
      "PT-141 mechanism",
      "melanocortin receptor peptide research",
      "PT-141 preclinical study",
      "PT-141 Vyleesi research",
      "cyclic melanocortin peptide",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "PT-141 (Bremelanotide) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as an agonist at melanocortin receptors MC3R and MC4R. This overview covers its structure, receptor pharmacology, published preclinical research, and laboratory specifications.",
    sections: [
      {
        heading: "What Is PT-141 (Bremelanotide)?",
        content:
          "PT-141, formally designated Bremelanotide, is a synthetic cyclic heptapeptide derived from the Melanotan II (MT-II) backbone via structural modification — specifically, removal of the N-terminal acetyl group and opening of the lactam ring to produce the linear precursor, followed by cyclization via a different chemistry. It is an analog of alpha-melanocyte-stimulating hormone (α-MSH), itself a cleavage product of pro-opiomelanocortin (POMC). Bremelanotide was approved by the FDA in 2019 under the brand name Vyleesi for a specific indication in premenopausal adults. The research reference material is an entirely distinct context from this approved therapeutic product.",
      },
      {
        heading: "Structural Properties",
        content:
          "PT-141 (Bremelanotide) is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, incorporating a non-natural amino acid (D-Phe at position 7 relative to α-MSH) and a lactam ring between the Asp and Lys side chains. This cyclic structure confers resistance to proteolytic degradation. The molecular weight is 1025.2 Da (C₅₀H₆₈N₁₄O₁₀).",
        list: [
          "Type: Cyclic heptapeptide",
          "Molecular weight: 1025.2 Da",
          "Formula: C₅₀H₆₈N₁₄O₁₀",
          "Key feature: Asp-Lys lactam ring for proteolytic stability",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "Melanocortin Receptor Pharmacology",
        content:
          "The melanocortin system consists of five G protein-coupled receptors (MC1R–MC5R). PT-141 acts primarily as an agonist at MC3R and MC4R, which are expressed in the central nervous system, particularly in the hypothalamus and limbic system. MC4R activation in the hypothalamus has been linked in animal model research to modulation of behavior, energy balance, and autonomic tone. Published receptor binding studies have characterized PT-141's binding affinities across the melanocortin receptor subtypes, with MC3R and MC4R showing the highest affinity constants relative to MC1R and MC5R.",
      },
      {
        heading: "Published Preclinical Research",
        content:
          "The published preclinical literature on PT-141 has examined MC3R and MC4R receptor binding kinetics, c-fos expression in hypothalamic nuclei following melanocortin receptor activation in rodent models, and behavioral assay outcomes in rodent studies. Research appearing in journals including European Journal of Pharmacology and Journal of Pharmacology and Experimental Therapeutics has characterized the compound's receptor selectivity profile and downstream signaling pathways. All preclinical findings do not constitute evidence of corresponding effects in humans.",
        list: [
          "MC3R/MC4R binding affinity characterization (in vitro)",
          "c-fos expression in hypothalamic nuclei (rodent models)",
          "cAMP signaling downstream of MC4R activation (in vitro)",
          "Melanocortin receptor selectivity profiling across MC1-5R subtypes",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade PT-141 (Bremelanotide) is supplied as a lyophilized powder at ≥99% HPLC purity. Mass spectrometry identity confirmation verifies the correct cyclic peptide molecular weight and lactam ring structure. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "PT-141 (Bremelanotide) reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical applications only. While Bremelanotide (Vyleesi) has FDA approval for a specific clinical indication, the research reference material supplied here is not intended for therapeutic use. Nothing in this article constitutes medical advice. Researchers should consult all applicable institutional and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "How is PT-141 structurally related to Melanotan II?",
        answer:
          "PT-141 (Bremelanotide) is derived from the Melanotan II (MT-II) scaffold. MT-II is a cyclic heptapeptide, and PT-141 is a modification of this structure. Both are cyclic analogs of α-MSH, but PT-141 was specifically developed as a research compound targeting MC3R/MC4R pharmacology with modifications intended to alter the activity profile relative to MT-II.",
      },
      {
        question: "Which melanocortin receptors does PT-141 primarily target in research models?",
        answer:
          "Published binding studies indicate that PT-141 (Bremelanotide) shows highest affinity for MC3R and MC4R, with lower affinity for MC1R, MC2R, and MC5R. MC4R, expressed in hypothalamic nuclei, has been the primary focus of published behavioral neuroscience research using this compound.",
      },
      {
        question: "What was PT-141 FDA-approved for?",
        answer:
          "Bremelanotide (Vyleesi) was approved by the FDA in 2019 for a specific indication in premenopausal adults. This approved clinical context is entirely separate from the research reference material supplied by Vertex Research Labs, which is intended for laboratory research only.",
      },
      {
        question: "What purity standard is required for research-grade PT-141?",
        answer:
          "≥99% purity by HPLC, confirmed by mass spectrometry identity verification of the cyclic peptide structure. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["pt-141"],
    relatedSlugs: [
      "melanotan-2-mt2-research",
      "kisspeptin-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "melanotan-2-mt2-research",
    title: "Melanotan 2 (MT-II) Research Overview: Melanocortin Agonist Studies",
    metaTitle: "Melanotan 2 MT-II Research Overview: Cyclic Melanocortin Peptide | Vertex Research Labs",
    metaDescription:
      "Research overview of Melanotan 2 (MT-II), the cyclic heptapeptide α-MSH analog. Covers structure, MC1R through MC5R receptor pharmacology, published pigmentation and behavior research in animal models, and lab specifications.",
    keywords: [
      "Melanotan 2 research",
      "MT-II research",
      "Melanotan II peptide research",
      "alpha MSH analog research",
      "melanocortin agonist research",
      "MT-II mechanism",
      "MT-II pigmentation research",
      "Melanotan 2 preclinical study",
      "MC1R melanocortin research",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "Melanotan 2 (MT-II) is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) developed as a research tool for studying melanocortin receptor pharmacology. This overview covers its structure, receptor binding profile across MC1R–MC5R, published preclinical literature, and laboratory specifications.",
    sections: [
      {
        heading: "What Is Melanotan 2 (MT-II)?",
        content:
          "Melanotan 2 (MT-II), formally Ac-Nle⁴-cyclo[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was developed in the 1980s at the University of Arizona as a more potent and metabolically stable melanocortin receptor agonist compared to the linear native hormone. The compound incorporates a D-phenylalanine substitution at position 7 and a lactam cyclization between Asp⁵ and Lys¹⁰ that confers resistance to enzymatic degradation. MT-II has become a widely used pharmacological tool in melanocortin receptor research.",
      },
      {
        heading: "Structural Properties",
        content:
          "MT-II is a cyclic heptapeptide with molecular weight approximately 1024.2 Da and molecular formula C₅₀H₆₉N₁₅O₉. The N-terminal acetylation and C-terminal amide, in combination with the Asp-Lys lactam bridge, define its structural distinction from linear α-MSH. The D-Phe substitution at position 7 is a key determinant of its enhanced receptor affinity and selectivity relative to native α-MSH.",
        list: [
          "Type: Cyclic heptapeptide",
          "Molecular weight: ~1024.2 Da",
          "Formula: C₅₀H₆₉N₁₅O₉",
          "Key modifications: D-Phe⁷, Asp-Lys lactam bridge, N-Ac, C-NH₂",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "Melanocortin Receptor Binding Profile",
        content:
          "MT-II is a pan-melanocortin receptor agonist with nanomolar binding affinity across MC1R, MC3R, MC4R, and MC5R. Published binding assay data has characterized its Ki values across receptor subtypes expressed in cell-based systems, with MC1R and MC4R typically showing the highest measured affinities. MC1R is expressed on melanocytes and plays a central role in eumelanin synthesis; MC3R and MC4R are expressed in the hypothalamus and CNS. This broad receptor profile distinguishes MT-II from more selective melanocortin agonists and makes it a reference tool for receptor pharmacology research across the full melanocortin family.",
      },
      {
        heading: "Published Preclinical Research",
        content:
          "The published MT-II literature spans multiple research domains including pigmentation biology, energy balance, and behavioral neuroscience. Key published studies have examined eumelanin synthesis in melanocyte cell cultures following MC1R activation, hypothalamic feeding behavior regulation in rodent models via MC4R, and the role of the melanocortin system in autonomic cardiovascular function in animal studies. Research appearing in Peptides, Journal of Investigative Dermatology, and Journal of Pharmacology and Experimental Therapeutics has used MT-II as a pharmacological probe. All cited findings represent preclinical or in vitro research.",
        list: [
          "Eumelanin synthesis in MC1R-expressing melanocyte cultures",
          "MC4R-mediated energy balance regulation in rodent models",
          "Hypothalamic melanocortin circuitry mapping studies",
          "Autonomic and cardiovascular MC receptor research in animal models",
          "Receptor selectivity comparisons vs. α-MSH and other melanocortin agonists",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade MT-II is supplied as a lyophilized powder at ≥99% purity by HPLC. Mass spectrometry confirms the cyclic peptide structure including the lactam bridge and correct molecular weight. At Vertex Research Labs, Certificates of Analysis are available on request where applicable.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "Melanotan 2 (MT-II) reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical applications only. This compound is not FDA-approved and is not intended for human or veterinary use. Nothing in this article constitutes medical advice or a health claim. Researchers should consult all applicable institutional and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "How does MT-II differ from PT-141 (Bremelanotide) in receptor pharmacology research?",
        answer:
          "MT-II is a pan-melanocortin agonist with activity at MC1R, MC3R, MC4R, and MC5R. PT-141 (Bremelanotide) is derived from the MT-II scaffold but was specifically developed with modifications that alter the receptor selectivity profile, with greater selectivity toward MC3R/MC4R. Published binding studies have quantified these differences across receptor subtypes.",
      },
      {
        question: "Why was D-Phe incorporated into the MT-II structure?",
        answer:
          "The D-phenylalanine (D-Phe) substitution at position 7 increases both receptor binding affinity and conformational stability compared to the native L-Phe. D-amino acid substitutions are commonly used in peptide research to improve bioactivity and resistance to enzymatic degradation.",
      },
      {
        question: "What research has examined MT-II and MC1R in pigmentation studies?",
        answer:
          "Published cell biology research has used MT-II as a pharmacological tool to stimulate MC1R on melanocytes, examining downstream cAMP signaling and eumelanin production. These are in vitro cell culture studies of pigmentation biology and do not represent clinical findings.",
      },
      {
        question: "What purity is required for research-grade MT-II?",
        answer:
          "≥99% purity by HPLC is the standard, confirmed by mass spectrometry identity verification of the cyclic peptide structure. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["mt2"],
    relatedSlugs: [
      "pt-141-bremelanotide-research",
      "kisspeptin-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "dsip-delta-sleep-inducing-peptide-research",
    title: "DSIP Research Overview: Delta Sleep-Inducing Peptide and Sleep Biology Studies",
    metaTitle: "DSIP Research Overview: Delta Sleep-Inducing Peptide Studies | Vertex Research Labs",
    metaDescription:
      "Research overview of DSIP (Delta Sleep-Inducing Peptide), the nonapeptide isolated from rabbit thalamus. Covers structure, published EEG sleep studies in animal models, stress hormone research, and laboratory specifications.",
    keywords: [
      "DSIP research",
      "delta sleep inducing peptide research",
      "DSIP peptide research",
      "DSIP mechanism",
      "DSIP sleep research",
      "DSIP EEG study",
      "DSIP stress hormone research",
      "DSIP nonapeptide research",
      "sleep peptide research",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 7,
    excerpt:
      "DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide originally isolated from rabbit thalamus venous blood that has been studied in the context of slow-wave sleep EEG patterns, stress hormone regulation, and neuropeptide biology. This overview covers its discovery, structure, published research, and laboratory specifications.",
    sections: [
      {
        heading: "What Is DSIP?",
        content:
          "Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code: WAGGDASGE) and a molecular weight of 848.9 Da. It was first isolated and characterized in 1977 by Marcel Monnier and colleagues from the thalamic venous blood of rabbits during deep slow-wave sleep induction experiments. The peptide has been detected in peripheral blood, cerebrospinal fluid, hypothalamus, pituitary, and limbic system tissue in published studies using various species. DSIP does not act through a clearly defined single receptor; its molecular targets and mechanisms remain an active area of investigation in the published literature.",
      },
      {
        heading: "Structural Properties",
        content:
          "DSIP is a linear nonapeptide with no disulfide bonds or cyclic structure. Its molecular formula is C₃₅H₄₈N₁₀O₁₅ and molecular weight is 848.9 Da. DSIP is water-soluble and relatively susceptible to proteolytic degradation compared to cyclic peptides, which has been noted in published pharmacokinetic studies in animal models. For laboratory use it is supplied as a lyophilized powder requiring reconstitution in aqueous buffer.",
        list: [
          "Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (9 amino acids)",
          "Molecular weight: 848.9 Da",
          "Formula: C₃₅H₄₈N₁₀O₁₅",
          "Structure: Linear, no disulfide bonds",
          "Standard research purity: ≥99% by HPLC",
        ],
      },
      {
        heading: "EEG Sleep Research in Animal Models",
        content:
          "The published literature on DSIP originated from EEG-based sleep studies in rabbits and subsequently rodents. Monnier's original 1977 publications in Pflügers Archiv reported that perfusion of DSIP in recipient rabbits increased slow-wave (delta) EEG activity, giving the peptide its name. Subsequent published animal research has examined DSIP administration in rodent sleep architecture studies, measuring changes in delta wave power, REM sleep distribution, and sleep latency in various experimental contexts. These represent preclinical animal model findings only and do not demonstrate corresponding effects in humans.",
      },
      {
        heading: "Stress Hormone and Neuroendocrine Research",
        content:
          "Beyond sleep EEG studies, published research has examined DSIP in the context of stress hormone modulation. Animal model studies have investigated DSIP's interaction with the hypothalamic-pituitary-adrenal (HPA) axis, reporting effects on ACTH and corticosterone levels in rodents. Additional published work has examined DSIP and circadian rhythm parameters, LH pulsatility, and antioxidant enzyme activity in preclinical models. The molecular mechanism linking DSIP to these diverse biological endpoints is not fully characterized in the published literature, making it an active research puzzle.",
        list: [
          "ACTH and corticosterone modulation in rodent models",
          "HPA axis interaction studies in preclinical research",
          "LH pulsatility research in animal models",
          "Antioxidant enzyme activity assays (preclinical)",
          "Circadian rhythm parameter studies in rodent models",
        ],
      },
      {
        heading: "Laboratory Specifications",
        content:
          "Research-grade DSIP is supplied as a lyophilized powder at ≥99% purity by HPLC. Mass spectrometry confirms the correct nonapeptide sequence and molecular weight of 848.9 Da. At Vertex Research Labs, Certificates of Analysis are available on request where applicable. DSIP should be stored desiccated at -20°C and protected from repeated freeze-thaw cycles.",
      },
      {
        heading: "Research Disclaimer",
        content:
          "DSIP reference materials from Vertex Research Labs are supplied for in vitro laboratory research and analytical applications only. This compound is not FDA-approved and is not intended for human or veterinary use. Nothing in this article constitutes medical advice. Researchers should consult all applicable institutional and regulatory guidelines before use.",
      },
    ],
    faqs: [
      {
        question: "Who first isolated DSIP and how was it discovered?",
        answer:
          "DSIP was first isolated and characterized by Marcel Monnier and colleagues in 1977 from thalamic venous blood of rabbits during slow-wave sleep induction experiments. The peptide was identified in effluent blood from the thalamus during induced delta sleep and named for the associated EEG pattern.",
      },
      {
        question: "What EEG findings have been reported for DSIP in animal model research?",
        answer:
          "Published animal model research has reported increases in slow-wave (delta) EEG power following DSIP administration in rabbits and rodents. Subsequent studies have examined changes in sleep architecture including delta wave duration, sleep latency, and REM distribution. These are preclinical findings only.",
      },
      {
        question: "Does DSIP have a known receptor?",
        answer:
          "A specific DSIP receptor has not been definitively characterized in the published literature, which distinguishes it from most neuropeptides with well-defined receptor families. Its molecular targets and downstream signaling pathways remain an active area of investigation, contributing to ongoing research interest.",
      },
      {
        question: "What purity standard is required for research-grade DSIP?",
        answer:
          "≥99% purity by HPLC is the standard for research-grade DSIP, confirmed alongside mass spectrometry identity verification. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["dsip"],
    relatedSlugs: [
      "epithalon-research-overview",
      "semax-research-overview",
      "research-grade-peptide-purity-standards",
    ],
  },

  {
    slug: "wolverine-blend-peptide-research",
    title: "Wolverine Blend Research Overview: BPC-157 and TB-500 Combination Studies",
    metaTitle: "Wolverine Blend Research: BPC-157 + TB-500 Peptide Combination | Vertex Research Labs",
    metaDescription:
      "Research overview of the Wolverine Blend — a co-formulated BPC-157 and TB-500 peptide combination. Covers the published research on each component, their proposed complementary mechanisms in preclinical studies, and laboratory specifications.",
    keywords: [
      "Wolverine blend research",
      "BPC-157 TB-500 blend research",
      "BPC-157 TB-500 combination research",
      "peptide blend research",
      "Wolverine blend peptide study",
      "BPC-157 TB-500 mechanism",
      "combined peptide research",
      "TB-500 BPC-157 preclinical",
      "research peptide blend",
    ],
    publishedDate: "2025-05-01",
    modifiedDate: "2025-05-27",
    category: "Research Overview",
    readTime: 8,
    excerpt:
      "The Wolverine Blend co-formulates BPC-157 (Body Protection Compound 157) and TB-500 (Thymosin Beta-4 fragment) in a single research vial. This overview covers the published preclinical research on each component, the proposed complementary signaling interactions studied in the literature, and laboratory specifications for the combination.",
    sections: [
      {
        heading: "What Is the Wolverine Blend?",
        content:
          "The Wolverine Blend is a co-formulated research preparation containing BPC-157 (Body Protection Compound 157, a synthetic pentadecapeptide) and TB-500 (a synthetic analog of the Thymosin Beta-4 fragment Ac-SDKP). The blend is available as a single lyophilized vial for researchers who wish to study both peptides in parallel experimental protocols without preparing separate reconstitutions. Each component has an independent published preclinical literature base, and the combination is of interest to researchers studying complementary mechanisms of tissue signaling in animal models. The Wolverine Blend is a research reference preparation only, not a pharmaceutical product.",
      },
      {
        heading: "BPC-157 Component: Research Background",
        content:
          "BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino-acid pentadecapeptide derived from a protective gastric protein sequence. The majority of published BPC-157 research originates from the University of Zagreb group led by Professor Predrag Sikiric. Published rodent model studies have examined BPC-157's interactions with nitric oxide (NO) signaling, vascular endothelial growth factor receptor 2 (VEGFR2) expression, focal adhesion kinase (FAK), and cytoskeletal dynamics. Research has also examined gut motility models, tendon-to-bone healing models, and angiogenesis parameters in animal studies. All findings represent preclinical research only.",
        list: [
          "Molecular weight: ~1419.5 Da",
          "Length: 15 amino acids (pentadecapeptide)",
          "Key research focus: NO pathway, VEGFR2, FAK in rodent models",
          "Primary research group: Sikiric laboratory, University of Zagreb",
        ],
      },
      {
        heading: "TB-500 Component: Research Background",
        content:
          "TB-500 is a synthetic peptide corresponding to the active fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein highly expressed in platelets and wound fluid. The research-relevant fragment is the actin-binding tetrapeptide Ac-Ser-Asp-Lys-Pro (Ac-SDKP), which is the minimal sequence that retains actin G-actin sequestering activity in cell-based assays. Published research appearing in Nature Medicine, Journal of Molecular Biology, and The FASEB Journal has examined Tβ4 and the Ac-SDKP fragment in actin dynamics research, endothelial cell migration assays, and angiogenesis models in rodents and cell culture. TB-500 purity should be ≥99% by HPLC for research use.",
        list: [
          "Active fragment: Ac-Ser-Asp-Lys-Pro (Ac-SDKP tetrapeptide)",
          "Parent protein: Thymosin Beta-4 (43 amino acids)",
          "Key research focus: actin sequestration, endothelial migration, angiogenesis",
          "Published journals: Nature Medicine, FASEB Journal, J. Mol. Biology",
        ],
      },
      {
        heading: "Proposed Complementary Research Interests",
        content:
          "Researchers studying tissue remodeling and vascular biology have noted that BPC-157 and TB-500 operate through distinct but potentially complementary signaling pathways in animal model research. BPC-157 research has focused on NO and VEGFR2-mediated angiogenesis and cytoskeletal reorganization. TB-500's Ac-SDKP fragment acts upstream in actin polymerization dynamics and has been studied in endothelial migration and tube formation assays. The overlap of interest in angiogenic signaling — approached from different mechanistic angles — has made the combination an area of preclinical research attention. No published studies have directly compared or combined the two peptides in controlled experiments to date.",
      },
      {
        heading: "Blend Specifications and Quality",
        content:
          "The Wolverine Blend from Vertex Research Labs contains both BPC-157 and TB-500 as verified research-grade components, each at ≥99% purity by HPLC. The blend is supplied as a co-lyophilized powder in a sealed research vial. Where applicable, Certificate of Analysis documentation covering purity and identity (by mass spectrometry for both components) is available on request.",
        list: [
          "Components: BPC-157 (≥99% HPLC) + TB-500 (≥99% HPLC)",
          "Form: Co-lyophilized powder, single research vial",
          "COA: Available on request where applicable, covering identity and purity of both components",
          "Storage: Lyophilized at -20°C; reconstituted solution use promptly",
        ],
      },
      {
        heading: "Research Disclaimer",
        content:
          "The Wolverine Blend reference material from Vertex Research Labs is supplied for in vitro laboratory research and analytical applications only. Neither BPC-157 nor TB-500 is FDA-approved. This preparation is not intended for human or veterinary use. Nothing in this article constitutes medical advice or a therapeutic claim. Researchers should follow all applicable institutional biosafety and regulatory guidelines.",
      },
    ],
    faqs: [
      {
        question: "Why are BPC-157 and TB-500 often studied together in preclinical research?",
        answer:
          "Both BPC-157 and TB-500 have published preclinical literature in areas of vascular and tissue remodeling biology, though via distinct mechanisms — BPC-157 through NO/VEGFR2 signaling and TB-500's Ac-SDKP fragment through actin dynamics and endothelial migration. Researchers studying tissue repair biology have noted these complementary research profiles, motivating interest in studying them in the same experimental context.",
      },
      {
        question: "Are there published studies that have combined BPC-157 and TB-500 together?",
        answer:
          "As of the publication of this article, no peer-reviewed studies examining the two peptides in direct combination under controlled conditions have been identified in the published literature. The Wolverine Blend is designed for researchers who wish to run parallel or sequential single-compound experiments using verified-purity reference material for both.",
      },
      {
        question: "What is the active sequence in TB-500 that researchers study?",
        answer:
          "The pharmacologically active fragment of Thymosin Beta-4 studied in cell biology research is the N-terminal tetrapeptide Ac-Ser-Asp-Lys-Pro (Ac-SDKP). This tetrapeptide retains G-actin sequestering activity and has been used as a research tool in actin dynamics and endothelial migration assays.",
      },
      {
        question: "Does the Wolverine Blend COA cover both peptide components?",
        answer:
          "Where Certificate of Analysis documentation is available, it covers the identity and purity of both BPC-157 and TB-500 components individually, by HPLC and mass spectrometry for each peptide in the blend. Certificates of Analysis are available on request where applicable.",
      },
      {
        question: "What purity standards apply to each component in the Wolverine Blend?",
        answer:
          "Both BPC-157 and TB-500 in the Wolverine Blend are held to ≥99% HPLC purity standards, with each component verified independently before being combined into the research preparation. Certificates of Analysis are available on request where applicable.",
      },
    ],
    relatedProducts: ["wolverine-blend"],
    relatedSlugs: [
      "bpc-157-research-overview",
      "tb-500-thymosin-beta-4-research",
      "research-grade-peptide-purity-standards",
    ],
  },
];
